IN2014CN02616A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02616A
IN2014CN02616A IN2616CHN2014A IN2014CN02616A IN 2014CN02616 A IN2014CN02616 A IN 2014CN02616A IN 2616CHN2014 A IN2616CHN2014 A IN 2616CHN2014A IN 2014CN02616 A IN2014CN02616 A IN 2014CN02616A
Authority
IN
India
Prior art keywords
patients
present
invention refers
treatment protocol
diabetes type
Prior art date
Application number
Inventor
Louise Silvestre
Elisabeth Souhami
Xiaodan Wei
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of IN2014CN02616A publication Critical patent/IN2014CN02616A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention refers to a treatment protocol for diabetes type 2 patients.
IN2616CHN2014 2011-10-28 2012-10-26 IN2014CN02616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11187169 2011-10-28
PCT/EP2012/071271 WO2013060850A1 (en) 2011-10-28 2012-10-26 Treatment protocol of diabetes type 2

Publications (1)

Publication Number Publication Date
IN2014CN02616A true IN2014CN02616A (en) 2015-06-26

Family

ID=47071308

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2616CHN2014 IN2014CN02616A (en) 2011-10-28 2012-10-26

Country Status (16)

Country Link
US (1) US20130296236A1 (en)
EP (1) EP2771024B1 (en)
JP (1) JP6329487B2 (en)
KR (1) KR101967941B1 (en)
CN (2) CN107693783A (en)
AU (1) AU2012328388B2 (en)
BR (1) BR112014010200A2 (en)
CA (1) CA2851690C (en)
HK (1) HK1198577A1 (en)
IL (1) IL232251B (en)
IN (1) IN2014CN02616A (en)
MX (1) MX359329B (en)
MY (1) MY170713A (en)
RU (1) RU2014121386A (en)
SG (1) SG11201401175SA (en)
WO (1) WO2013060850A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043566A2 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
ES2855146T3 (en) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
PT2611458T (en) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PT2750699E (en) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
ES2688367T3 (en) 2012-12-21 2018-11-02 Sanofi Derivatives of exendin-4 as dual agonists of GLP1 / GIP or trigonal of GLP1 / GIP / glucagon
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2014209630A2 (en) * 2013-06-27 2014-12-31 Inspark Technologies, Inc. Systems, devices, and/or methods for identifying time periods of insufficient blood glucose testing
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (en) 2013-12-13 2016-03-16 賽諾菲公司 EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN112957455A (en) 2014-01-09 2021-06-15 赛诺菲 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107206058A (en) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 Insulin glargine/lixisenatide fixed ratio preparaton
AR103415A1 (en) * 2015-01-16 2017-05-10 Sanofi Aventis Deutschland TREATMENT OF PEDIATRIC PATIENTS WITH MELLITUS DIABETES OF TYPE 2
TWI748945B (en) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) * 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
JP2007504213A (en) * 2003-09-02 2007-03-01 プロシディオン・リミテッド Combination therapy for the treatment of glycemic control
CN101014360A (en) * 2004-08-03 2007-08-08 埃米斯菲尔技术公司 Antidiabetic oral insulin-biguanide combination
CN102369029A (en) * 2009-02-04 2012-03-07 赛诺菲-安万特德国有限公司 Medical device and method for providing information for glycemic control
JP5980466B2 (en) * 2009-11-13 2016-08-31 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Method for treating type 2 diabetes including addition therapy to insulin glargine and metformin
DK2329848T4 (en) * 2009-11-13 2019-09-09 Sanofi Aventis Deutschland Lixisenatide as adjunctive therapy to insulin glargine and metformin for the treatment of type 2 diabetes
KR20110052990A (en) * 2009-11-13 2011-05-19 사노피-아벤티스 도이칠란트 게엠베하 Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
US9821032B2 (en) * 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin

Also Published As

Publication number Publication date
EP2771024B1 (en) 2018-11-28
CA2851690C (en) 2022-07-26
AU2012328388A1 (en) 2014-05-15
SG11201401175SA (en) 2014-09-26
CN104066441A (en) 2014-09-24
KR20140093935A (en) 2014-07-29
CN107693783A (en) 2018-02-16
WO2013060850A1 (en) 2013-05-02
HK1198577A1 (en) 2015-04-30
MY170713A (en) 2019-08-27
MX2014005139A (en) 2014-08-27
JP6329487B2 (en) 2018-05-23
EP2771024A1 (en) 2014-09-03
RU2014121386A (en) 2015-12-10
IL232251B (en) 2019-10-31
US20130296236A1 (en) 2013-11-07
IL232251A0 (en) 2014-06-30
AU2012328388B2 (en) 2017-06-15
KR101967941B1 (en) 2019-04-10
JP2015501314A (en) 2015-01-15
CA2851690A1 (en) 2013-05-02
BR112014010200A2 (en) 2020-10-27
MX359329B (en) 2018-09-25

Similar Documents

Publication Publication Date Title
IN2014CN02616A (en)
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
MX370264B (en) Pharmaceutical combination for use in glycemic control in diabetes type 2 patients.
ZA201403795B (en) Formulations for the treatment of diabetes
AP2014007436A0 (en) A novel 1,2,3,4,-Tetrahydroquinoline derivative useful for the treatment of diabetes
AP2014007399A0 (en) Phenyl-3-AZA-bicycloÄ3.1.0Ühex-3-YL-methanones andthe use thereof as medicament
MX2015002487A (en) Process for the preparation of teneligliptin.
TW201144301A (en) Processes for preparing linezolid
MX349224B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease.
EA033171B1 (en) Semisolid aqueous pharmaceutical composition containing tapentadol
HK1206938A1 (en) Process for the preparation of 3-chloro-4,5,6-trifluoro- picolinonitrile 3--456--
MX2016004325A (en) Novel derivative of an insulin analogue.
MX357656B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases.
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
EP2646113A4 (en) .device for medical external treatment by light
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
EA201401045A1 (en) CONNECTIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH ISCHEMIA-REPERFUSION
WO2011161295A3 (en) Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation
UA65175U (en) Method of uranostaphyloplasty
MX356969B (en) A reduced-cholesterol dairy product for use as a medicament.
HK1196953A1 (en) Formulations for the treatment of diabetes
UA46473U (en) Method for treating age-related maculodystrophy
EP2627655A4 (en) Therapeutic 5,6,5-tricyclic analogs
UA97054C2 (en) Method for the treatment of patients with dependence owing to application of psychoactive substances